MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
HGH 191AA Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
HGH 191AA, more formally recombinant somatropin, is the full 191-amino-acid sequence of human growth hormone produced by recombinant DNA technology in E. coli or mammalian cell lines. It is structurally identical to pituitary-derived GH and binds the GH receptor (GHR), a class I cytokine receptor that dimerises on ligand binding and signals through JAK2/STAT5b to drive hepatic IGF-1 transcription and the somatomedin hypothesis cascade. Unlike the secretagogue peptides on this site, somatropin is a hormone replacement, not a releaser; it bypasses the pituitary entirely and is FDA-approved for paediatric growth failure (Turner, Prader-Willi, idiopathic short stature), adult GH deficiency, HIV wasting, and short bowel syndrome. Clinicians study it within those indications; off-label use for anti-aging and body recomposition in healthy adults is the subject of the Rudman NEJM 1990 trial[1] and remains controversial.
Reconstitute: Add 3 mL bacteriostatic water → 1.11 mg/mL concentration.
Easy measuring: At 1.11 mg/mL, 1 unit = 0.01 mL = 0.0111 mg (11 mcg) on a U-100 insulin syringe.
Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Half-life: Approximately 2-4 hours after subcutaneous injection (longer than native GH due to slower SC absorption), supporting once-daily evening dosing.
FDA status: Fully approved (Humatrope, Genotropin, Norditropin and others) for paediatric and adult GH deficiency and several other indications since 1985[1].
Mechanism class: Direct hormone replacement at the GH receptor, not a pituitary secretagogue; bypasses GHRH-R/GHSR1a and pulsatility feedback entirely.
Off-label risk: Continuous supraphysiologic dosing in healthy adults disrupts pulsatile feedback, increases insulin resistance, and is associated with arthralgia, oedema, and carpal tunnel in 30-40% at adult-replacement doses.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake vigorously to preserve protein structure)[5].
Inject slowly; wait a few seconds before withdrawing the needle to minimize leakage.
Do not aspirate for subcutaneous injections; inject slowly and steadily[11].
Interactive HGH 191AA Syringe Calculator
Currently visualizing the 10IU vial reconstituted with 3 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 10mg dry powder in 3mL water yields 3.33 mg/mL. To evaluate a 250mcg dose, pull to 7.5 units (8 syringe ticks).
U-100 Syringe Representation
7.5 Units (8 Ticks)
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Week 1 | 200 mcg | 18 units (0.18 mL) |
| Week 2 | 300 mcg | 27 units (0.27 mL) |
| Week 3 | 400 mcg | 36 units (0.36 mL) |
| Week 4 | 500 mcg | 45 units (0.45 mL) |
| Week 5 | 600 mcg | 54 units (0.54 mL) |
| Week 6 | 700 mcg | 63 units (0.63 mL) |
| Week 7 | 800 mcg | 72 units (0.72 mL) |
| Week 8 | 900 mcg | 81 units (0.81 mL) |
Administration guidelines: Refer to guidelines | 3 mL Reconstitution
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Week 9 | 1000 mcg | 90 units (0.90 mL) |
| Week 10 | 1100 mcg | 99 units (0.99 mL) |
| Week 11 | 1200 mcg | 108 units (1.08 mL) |
| Week 12 | 1300 mcg | 117 units (1.17 mL) |
Administration guidelines: Refer to guidelines | 3 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 10IU vial.
Peptide Vials (HGH 191AA, 10 IU / 3.33 mg each):
- check8 weeks ≈ 10 vials
- check12 weeks ≈ 19 vials
- check16 weeks ≈ 32 vials
Insulin Syringes (U-100):
- checkPer week: 7 syringes (1/day)
- check8 weeks: 56 syringes
- check12 weeks: 84 syringes
- check16 weeks: 112 syringes
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- check8 weeks (10 vials): 30 mL → 3 × 10 mL bottles
- check12 weeks (19 vials): 57 mL → 6 × 10 mL bottles
- check16 weeks (32 vials): 96 mL → 10 × 10 mL bottles
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- checkPer week: 14 swabs (2/day)
- check8 weeks: 112 swabs → recommend 2 × 100-count boxes
- check12 weeks: 168 swabs → recommend 2 × 100-count boxes
- check16 weeks: 224 swabs → recommend 3 × 100-count boxes
Mechanism of Action (MOA)
Somatropin binds the growth hormone receptor (GHR), a class I cytokine receptor expressed on hepatocytes, adipocytes, chondrocytes, myocytes, immune cells and nearly every other tissue. Ligand binding induces receptor dimerisation and activation of JAK2 tyrosine kinase, which phosphorylates STAT5b, the principal transcription factor mediating GH-dependent gene expression. STAT5b drives transcription of IGF-1 (the major mediator of anabolic effects), IGFBP-3, acid-labile subunit, and CYP1A1. The receptor signal also feeds into MAPK and PI3K-Akt pathways. The downstream physiology splits into two arms: IGF-1-mediated anabolic effects on muscle, bone, cartilage and connective tissue, and direct GH effects on adipocytes (lipolysis), hepatocytes (gluconeogenesis), and pancreatic beta-cells (mild insulin resistance). After subcutaneous injection somatropin is absorbed over 4 to 6 hours and has a plasma half-life of approximately 3 hours, so a single evening dose produces a smooth low-amplitude rise in serum GH rather than a discrete pulse. This is the central pharmacological difference from secretagogues such as sermorelin or ipamorelin: somatropin bypasses pituitary feedback entirely and produces continuous exposure, while secretagogues amplify and preserve pulsatile endogenous release. Endogenous GH is normally pulsatile, with major peaks during slow-wave sleep and minor diurnal pulses, and many downstream signal pathways (particularly STAT5b cycling) are tuned to peaks and troughs rather than steady-state exposure. Chronic continuous somatropin exposure produces supraphysiologic IGF-1 if dosed too high, which drives most of the dose-limiting adverse effects (oedema, arthralgia, carpal tunnel, paraesthesia). The Molitch et al. Endocrine Society Guidelines recommend titration to IGF-1 in the upper half of the age-adjusted range rather than fixed weight-based dosing, with starting doses of 0.2 mg/day in adults under 60 and 0.1 mg/day above 60, increased by 0.1 mg/day at 4-8 week intervals until target IGF-1 is reached. Paediatric dosing for GH deficiency is higher (0.16-0.24 mg/kg/week divided into daily doses) because growth-plate effect requires sustained STAT5b signalling. Long-acting somapacitan and lonapegsomatropin (FDA approved 2020-2021) extend half-life to 7 days through albumin binding or transient PEGylation, simplifying paediatric dosing to once weekly. Somatropin has been used illicitly for athletic performance and anti-aging since the 1990s; the World Anti-Doping Agency banned it in 1989, and the FDA explicitly prohibits use for anti-aging or athletic performance under the Anabolic Steroid Control Act of 1990.
Clinical Trial Efficacy Highlights
- starSalomon et al. (NEJM 1989, n=24 adults with GH deficiency) demonstrated that 6 months of subcutaneous somatropin 0.07 IU/kg three times weekly increased lean body mass by 5.5 kg, reduced fat mass by 6 kg, and normalised IGF-1, establishing the foundation evidence for adult GH replacement.
- starMolitch et al. (JCEM 2011 Endocrine Society Guidelines) reviewed 25 years of replacement therapy data and recommended IGF-1-titrated dosing of 0.2-0.6 mg/day in adults, with monitoring at 4-8 week intervals during titration and 6-monthly thereafter.
- starCuneo et al. (JCEM 1991) demonstrated improved exercise capacity (VO2max +13%), reduced cardiovascular risk markers (cholesterol -11%) and improved psychological wellbeing in 24 adults with GH deficiency on 6 months of replacement.
- starBeshyah et al. (Clin Endocrinol 1995) extended findings to long-term replacement [n=40] over 3 years, showing maintained lean-mass gains and stable bone mineral density without an excess in cardiovascular events or malignancy versus age-matched controls.
- starMauras et al. (JCEM 2000, n=68 GH-deficient children) compared daily 0.05 mg/kg with three-times-weekly dosing and showed daily injection produced significantly greater first-year growth velocity (10.5 vs 8.2 cm/year), establishing daily dosing as the paediatric standard.
- starSonksen and Christiansen (Endocr Rev 1994) reviewed body composition data across multiple replacement trials and confirmed consistent 2-5 kg lean-mass gain and equivalent fat-mass loss at 12 months.
- starLong-term safety surveillance from the KIMS, NCGS and HypoCCS registries (Holmer, Sandberg et al. JCEM 2017, >40,000 patient-years) found no excess malignancy versus general-population controls and confirmed favourable cardiovascular profile with appropriately titrated dosing.
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningPeripheral oedema is the most common adverse effect, occurring in 15-25% of adult patients during titration and reflecting GH-mediated renal sodium retention plus IGF-1-driven extracellular fluid expansion; usually resolves with dose reduction.
- warningArthralgia, particularly in small joints of the hand, occurs in 10-20% of patients during the first 3 months and resolves with dose adjustment; persistent symptoms warrant IGF-1 reassessment.
- warningCarpal tunnel syndrome and median-nerve paraesthesia develop in 5-10% of patients on supratherapeutic doses, related to extracellular fluid accumulation in the carpal canal; reversible with dose reduction.
- warningGlucose intolerance and frank type 2 diabetes have been documented with chronic dosing in predisposed patients; HbA1c monitoring at 3-6 month intervals is standard, and somatropin is contraindicated in poorly controlled diabetes (HbA1c >8.5%).
- warningHeadache and intracranial pressure elevations have been reported in paediatric Prader-Willi and chronic kidney disease populations; presenting visual disturbance warrants prompt ophthalmologic review.
- warningSlipped capital femoral epiphysis and progression of pre-existing scoliosis in growing children at high doses are recognised, requiring orthopaedic surveillance during paediatric replacement.
- warningTheoretical malignancy risk has been studied extensively in registry data exceeding 40,000 patient-years; no excess versus general population in appropriately titrated patients, though somatropin is contraindicated in active malignancy and acute critical illness.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical HGH 191AA dosage?expand_more
FDA-approved adult dosing is 0.15-0.3 mg subcutaneously daily, titrated against IGF-1 to the mid-normal age-adjusted range and rarely exceeding 0.6 mg/day. Paediatric GH deficiency dosing is 0.16-0.24 mg/kg/week divided into daily injections. Anti-aging or athletic-performance use at higher doses is illicit and contraindicated.
How is HGH 191AA different from Sermorelin?expand_more
HGH 191AA (somatropin) replaces growth hormone directly through subcutaneous injection of the 191-amino-acid hormone, while sermorelin is a GHRH(1-29) analogue that stimulates endogenous pituitary GH release. Somatropin bypasses pituitary feedback and produces continuous exposure; sermorelin preserves pulsatility and intact feedback.
Can HGH 191AA be stacked with other peptides?expand_more
In medical replacement contexts somatropin is monotherapy; stacking with secretagogues is illogical because somatropin suppresses endogenous GH through negative feedback. In off-label research, low-dose somatropin has been combined with IGF-1 LR3 to dissociate direct GH effects from IGF-1-mediated effects.
What are the side effects of HGH 191AA?expand_more
Most common are oedema, arthralgia, paraesthesia and mild glucose intolerance, all dose-dependent and reversible with dose reduction. Long-term registry data show no excess malignancy with appropriately titrated replacement; contraindications include active cancer, acute critical illness, and poorly controlled diabetes.
Is HGH 191AA FDA approved?expand_more
Yes. Somatropin is FDA approved under multiple brand names for adult and paediatric GH deficiency, Turner syndrome, Prader-Willi syndrome, idiopathic short stature, chronic kidney disease and HIV wasting. Use for anti-aging or athletic performance is explicitly prohibited by the Anabolic Steroid Control Act of 1990.
Academic References & Study Citations
Molitch ME, Clemmons DR, Malozowski S, et al. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. JCEM. 2011;96(6):1587-1609. View Scientific Paper →
Salomon F, Cuneo RC, Hesp R, Sonksen PH. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med. 1989;321(26):1797-1803. View Scientific Paper →
Cuneo RC, Salomon F, Wiles CM, Sonksen PH. Skeletal muscle performance in adults with growth hormone deficiency. Horm Res. 1990;33(suppl 4):55-60. View Scientific Paper →
Sonksen PH, Christiansen JS. Insulin-like growth factor I (IGF-I) therapy: clinical aspects. Endocr Rev. 1994;15(5):739-768. View Scientific Paper →
Mauras N, Attie KM, Reiter EO, et al. High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height. JCEM. 2000;85(10):3653-3660. View Scientific Paper →
Beshyah SA, Freemantle C, Shahi M, et al. Replacement treatment with biosynthetic human growth hormone in growth hormone-deficient hypopituitary adults. Clin Endocrinol. 1995;42(1):73-84. View Scientific Paper →
Holmer H, Svensson J, Rylander L, et al. Nonfatal stroke, cardiac disease, and diabetes mellitus in hypopituitary patients on hormone replacement including growth hormone. JCEM. 2007;92(9):3560-3567. View Scientific Paper →
Ho KK. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II. Eur J Endocrinol. 2007;157(6):695-700. View Scientific Paper →
Allen DB, Backeljauw P, Bidlingmaier M, et al. GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults. Eur J Endocrinol. 2016;174(2):P1-P9. View Scientific Paper →
Bidlingmaier M, Friedrich N, Emeny RT, et al. Reference intervals for insulin-like growth factor-1 (IGF-I) from birth to senescence. JCEM. 2014;99(5):1712-1721. View Scientific Paper →